The authors aimed to assess whether the combination of letrozole, metronomic cyclophosphamide and sorafenib (LCS) is well tolerated and shows activity in primary breast cancer (BC). The LCS combination is feasible and tolerable. the tumour response and target biomarker modulation indicate that the combination is clinically and biologically active.

READ FULL ARTICLE Curated publisher From Mdlinx